Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and Director of Breast Cancer Translational Research at Northwell Health, shared a post on LinkedIn by Cold Spring Harbor Laboratory, adding:
“It is a privilege to collaborate with Dr. David Spector and the team at Cold Spring Harbor Laboratory on breast cancer research.
Bringing together their strength in basic science with expertise in patient care at Northwell Cancer Institute is a vital step toward meaningful progress. Northwell Health is making a mark in the communities we serve.
Funding from National Cancer Institute (NCI) is now more important than ever.”
Cold Spring Harbor Laboratory shared a post by Northwell Cancer Institute, adding:
“This World Breast Cancer Research Day, go behind the bench and into the clinic—where CSHL scientists and Northwell Cancer Institute clinicians are working together to tackle triple-negative breast cancer and drive the breakthroughs patients need.”
Quoting Northwell Cancer Institute‘s post:
“Breast cancer is one of the most common cancers among women in the United States. Thanks to decades of fundamental research, it’s also one of the most curable.
Our expert Francisco J. Esteva, division chief of hematology/oncology at Lenox Hill Hospital collaborates with professor David Spector at the Cold Spring Harbor Laboratory on an aggressive variant known as triple-negative breast cancer (TNBC).
No effective therapies exist for TNBC, but this new research collaboration could help point us to the first.
Learn more about this new research.”
Watch the video attached to this post.
More posts featuring Francisco J. Esteva on OncoDaily.